ARS Pharmaceuticals (SPRY) EBITDA Margin (2022 - 2026)
ARS Pharmaceuticals' EBITDA Margin was -181.38% in Q2 2026, up 119.79 percentage points from -301.17% a year earlier and up 82.05 percentage points from the prior quarter.
Powered by 
Analysis
ARS Pharmaceuticals (SPRY) EBITDA Margin (2022 - 2026) Analysis & Trends
On a trailing twelve-month basis, ARS Pharmaceuticals' EBITDA Margin was -183.57% through Jun 30, 2026, down 131.36 percentage points year-over-year; for FY2025, it came in at -211.30%, down 207.93 percentage points from FY2024.
- EBITDA Margin shows a four-year change of +138.15 percentage points (FY2021 to FY2025).
- In earlier years, EBITDA Margin was -3.37% in FY2024 (+224729.96 pp), -224733.33% in FY2023 (-222042.15 pp), -2691.19% in FY2022 (-2341.73 pp) and -349.46% in FY2021.
- Quarterly EBITDA Margin has moved between -205830.00% (Q2 2023) and 54.55% (Q4 2024) over five years.
- Compared with a year earlier, EBITDA Margin was higher in four of the last five quarters, with an average year-over-year change of +753.20 percentage points.
- The best year-over-year quarter for EBITDA Margin over five years was Q2 2024 (a gain of 202765.60 percentage points); the worst was Q2 2023 (a drop of 204454.78 percentage points).
- Per Business Quant data, SPRY's EBITDA Margin in the three quarters before Q2 2026 was -263.43% (Q1 2026), -146.15% (Q4 2025) and -162.46% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | ARS Pharmaceuticals | 410.68 Mn | 266.88 Mn | 20.81 Mn | -181.38% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -181.38% |
| Mar 31, 2026 | -263.43% |
| Dec 31, 2025 | -146.15% |
| Sep 30, 2025 | -162.46% |
| Jun 30, 2025 | -301.17% |
| Mar 31, 2025 | -462.77% |
| Dec 31, 2024 | 54.55% |
| Sep 30, 2024 | -1,046.81% |
| Jun 30, 2024 | -3,064.40% |
| Jun 30, 2023 | -205,830.00% |
| Mar 31, 2023 | -93,465.00% |
| Sep 30, 2022 | -3,504.23% |
| Jun 30, 2022 | -1,375.22% |
| Mar 31, 2022 | -1,039.52% |
API Access
ARS Pharmaceuticals EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=SPRY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "SPRY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=SPRY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();